CPA
GYRE icon

Capital Performance Advisors’s Gyre Therapeutics GYRE Stock Holding History

Capital Performance Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6
Closed -$75 – 1202
2024
Q3 		$75 Buy
+6
New +$77 ﹤0.01% 2747

Other funds holding GYRE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's GYRE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2024, closing a stake of 6 shares — an estimated $75 sold.

Capital Performance Advisors first reported a position in GYRE in Q3 2024 and held it in 1 quarter. The position peaked at $75 in Q3 2024. 41 funds tracked by Wall St. Rank hold GYRE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Gyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 6 Gyre Therapeutics shares in Q4 2024, an estimated $75.
  • Capital Performance Advisors first reported a position in Gyre Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Gyre Therapeutics position peaked at $75 in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.